Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

COMMENTED

Macular DiseasesRetinal Diseases

Psoriasis as a Predictor of Neovascular Age-Related Macular Degeneration in Type 2 Diabetes Mellitus: A Nationwide Cohort Study

★ 3 Recommended and commented by Prof. emer. Dr Josef Flammer, Faculty Member

Am J Ophthalmol

Lee MY, Han K, Min KH, Yu DS, Lee YB

doi: 10.1016/j.ajo.2024.08.033

Macular Diseases

MERLIN: Two-Year Results of Brolucizumab in Participants With Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Ophthalmology

Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Heier JS, Khanani AM

doi: 10.1016/j.ophtha.2024.08.022

Macular Diseases

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Ophthalmol Ther

Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, Vujosevic S, Otoole L, Puzo M, Creuzot-Garcher C, Wolff B, Daien V, Fight Retinal Blindness! Study Group

doi: 10.1007/s40123-024-00983-2

Macular Diseases

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Acta Ophthalmol

Falemban AH, Söderberg-Löfdal K, Jonsson F, Almlöf-Sarman S, von Euler M, Westborg I

doi: 10.1111/aos.17534

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ophthalmol Retina

Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG

doi: 10.1016/j.oret.2025.05.030

Macular Diseases

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Br J Ophthalmol

Vu TA, Fenwick EK, Man REK, Thakur S, Tan ACS, Cheung CMG, Gupta P, Lamoureux EL

doi: 10.1136/bjo-2024-325713

Glaucoma and Ocular PressureRetinal Diseases

Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study

Br J Ophthalmol

Paris A, Volpe G, Perruchoud-Ader K, Casanova A, Menghini M, Grimaldi G

doi: 10.1136/bjo-2024-326053

Related content

Psoriasis as a Predictor of Neovascular Age-Related Macular Degeneration in Type 2 Diabetes Mellitus: A Nationwide Cohort Study

MERLIN: Two-Year Results of Brolucizumab in Participants With Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study